Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Cyclopharm Limited ( (AU:CYC) ) is now available.
Cyclopharm’s chairman told the 2026 AGM that 2025 was a year of disciplined execution, with group sales revenue rising 17% to a record $32.3 million, driven by a 226% surge in U.S. Technegas sales after Medicare reimbursement and 26% growth in its third‑party distribution arm. The U.S. has become the company’s largest single Technegas market, with 55 revenue-generating sites, a substantial pipeline, guidance for 250–300 U.S. installations in the second half of 2026, and fresh capital of $14.2 million earmarked to accelerate expansion, while new clinical guidelines naming Technegas as the preferred ventilation agent are expected to further support adoption and underpin long-term growth.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an Australian radiopharmaceutical company focused on diagnostic imaging, best known for its Technegas ventilation imaging agent used in lung scanning. The group also operates a third-party distribution business supplying complementary nuclear medicine products to hospitals and imaging centres across more than 60 international markets, with a growing emphasis on the United States.
Average Trading Volume: 122,155
Technical Sentiment Signal: Sell
Current Market Cap: A$92.66M
Learn more about CYC stock on TipRanks’ Stock Analysis page.